Literature DB >> 24792887

Aptamer TY04 inhibits the growth of multiple myeloma cells via cell cycle arrest.

Hongjuan Dai1, Mao Ye, Mingyuan Peng, Weihua Zhou, Huarong Bai, Xiaojuan Xiao, Bianying Ma, Jiajie Zhou, Shijun Tang, Shan Yao, Ye Cao, Zhiqiang Qin, Jing Liu, Weihong Tan.   

Abstract

The aptamer TY04 is a single-stranded DNA. However, its biological function has not been elucidated. Here, we found that TY04 specifically bound to multiple myeloma cells MM.1S, and some membrane proteins on the surface of MM.1S cells constituted the target molecules of TY04. TY04 inhibited the growth of multiple myeloma cell lines, induced cell cycle arrest in mitosis, and resulted in a significant accumulation of binucleated cells. Following TY04 treatment, a concomitant increase in CDK1 and cyclin B1 expression occurred. In addition, TY04 treatment also resulted in a significant downregulation of γ-tubulin. Considering the unique advantages of aptamers, TY04 shows great potential as a drug candidate to treat multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24792887     DOI: 10.1007/s13277-014-1920-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

1.  Development of DNA aptamers using Cell-SELEX.

Authors:  Kwame Sefah; Dihua Shangguan; Xiangling Xiong; Meghan B O'Donoghue; Weihong Tan
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

Review 2.  Microtubule nucleation.

Authors:  Didier Job; Odile Valiron; Berl Oakley
Journal:  Curr Opin Cell Biol       Date:  2003-02       Impact factor: 8.382

Review 3.  Multiple myeloma: treatment options for an incurable disease.

Authors:  S R Pandit
Journal:  J Assoc Physicians India       Date:  2005-12

Review 4.  Discovery and development of anticancer aptamers.

Authors:  Christopher R Ireson; Lloyd R Kelland
Journal:  Mol Cancer Ther       Date:  2006-12       Impact factor: 6.261

5.  Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.

Authors:  Sridharan Soundararajan; Li Wang; Vijayalakshmi Sridharan; Weiwei Chen; Nigel Courtenay-Luck; David Jones; Eleanor K Spicer; Daniel J Fernandes
Journal:  Mol Pharmacol       Date:  2009-08-05       Impact factor: 4.436

Review 6.  Nucleic acid aptamers: an emerging frontier in cancer therapy.

Authors:  Guizhi Zhu; Mao Ye; Michael J Donovan; Erqun Song; Zilong Zhao; Weihong Tan
Journal:  Chem Commun (Camb)       Date:  2012-11-04       Impact factor: 6.222

Review 7.  Generating aptamers by cell-SELEX for applications in molecular medicine.

Authors:  Mao Ye; Jun Hu; Minyuan Peng; Jing Liu; Jun Liu; Huixia Liu; Xielan Zhao; Weihong Tan
Journal:  Int J Mol Sci       Date:  2012-03-12       Impact factor: 6.208

8.  A transient association of gamma-tubulin at the midbody is required for the completion of cytokinesis during the mammalian cell division.

Authors:  H B Shu; Z Li; M J Palacios; Q Li; H C Joshi
Journal:  J Cell Sci       Date:  1995-09       Impact factor: 5.285

9.  Differential SELEX in human glioma cell lines.

Authors:  Laura Cerchia; Carla Lucia Esposito; Andreas H Jacobs; Bertrand Tavitian; Vittorio de Franciscis
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more
  4 in total

Review 1.  Advances in the development of aptamer drug conjugates for targeted drug delivery.

Authors:  Ke Chen; Bo Liu; Bo Yu; Wen Zhong; Yi Lu; Jiani Zhang; Jie Liao; Jun Liu; Ying Pu; Liping Qiu; Liqin Zhang; Huixia Liu; Weihong Tan
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-10-31

2.  Effects of β-catenin on differentially expressed genes in multiple myeloma.

Authors:  Hui Chen; Wei Chai; Bin Li; Ming Ni; Guo-Qiang Zhang; Hua-Wei Liu; Zhuo Zhang; Ji-Ying Chen; Yong-Gang Zhou; Yan Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

Review 3.  Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment.

Authors:  Gianfranco Lapietra; Francesca Fazio; Maria Teresa Petrucci
Journal:  Biomolecules       Date:  2022-08-19

4.  Targeting c-met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma.

Authors:  Yibin Zhang; Hongmei Gao; Weihua Zhou; Sunming Sun; Yayue Zeng; Hui Zhang; Long Liang; Xiaojuan Xiao; Jianhui Song; Mao Ye; Yujia Yang; Jingfeng Zhao; Zi Wang; Jing Liu
Journal:  J Cell Mol Med       Date:  2018-10-24       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.